Disalt inhibitors of il-12 production

Abstract

This invention relates to disalt nitrogen-heteroaryl inhibitors of IL-12 production, and related methods and pharmaceutical compositions.

1 .- 55 . (canceled) 
   
   
       56 . A method for treating an interleukin-12 overproduction-related disorder, comprising administering to a subject in need thereof an effective amount of a disalt represented by formula: 
     
       
         
         
             
             
         
       
       each M −  is a conjugate base of a Bronsted acid. 
     
   
   
       57 - 62 . (canceled) 
   
   
       63 . The method of  claim 56 , wherein the disorder is selected from the group consisting of multiple sclerosis, sepsis, myasthenia gravis, autoimmune neuropathies, Guillain-Barré syndrome, autoimmune uveitis, autoimmune hemolytic anemia, pernicious anemia, autoimmune thrombocopenia, temporal arteritis, anti-phospholipid syndrome, vasculitides, Wegener's granulomatosis, Behcet's disease, psoriasis, psoriatic arthritis, dermatitis herpetiformis, pemphigus vulgaris, vitiligo, Crohn's disease, ulcerative colitis, interstitial pulmonary fibrosis, myelofibrosis, hepatic fibrosis, myocarditis, thyroditis, primary biliary cirrhosis, autoimmune hepatitis, immune-mediated diabetes mellitus, Grave's disease, Hashimoto's thyroiditis, autoimmune oophoritis and orchitis, autoimmune disease of the adrenal gland; rheumatoid arthritis, juvenile rheumatoid arthritis, systemic lupus erythematosus, scleroderma, polymyositis, dermatomyositis, spondyloarthropathies, ankylosing spondylitis, Sjogren's syndrome and graft-versus-host disease. 
   
   
       64 . The method of  claim 63 , wherein the disorder is rheumatoid arthritis, sepsis, Crohn's disease, multiple sclerosis, psoriasis, or immune-mediated diabetes mellitus. 
   
   
       65 . A method of treating or preventing an inflammatory disorder in a subject in need of such treatment, comprising administering to the subject an effective amount of a disalt represented by formula: 
     
       
         
         
             
             
         
       
       each M −  is a conjugate base of a Bronsted acid. 
     
   
   
       66 . A method of treating an immune disease in a subject in need of such treatment, comprising administering to the subject an effective amount of a disalt represented by formula: 
     
       
         
         
             
             
         
       
       each M −  is a conjugate base of a Bronsted acid. 
     
   
   
       67 . The method according to  claim 56 , wherein M −  in the disalt is the conjugate base of a Bronsted acid selected from the group consisting of hydrochloric acid, nitric acid, sulfuric acid, hydrobromic acid, hydroiodic acid, perchloric acid, phosphoric acid, alkylsulfonic acids, arylsulfonic acids, halogenated alkylsulfonic acids, halogenated acetic acids, picric acid, oxalic acid, citric acid, formic acid, ascorbic acid and benzoic acid. 
   
   
       68 . The method of  claim 67 , wherein M −  is methanesulfonate, bromide, or chloride. 
   
   
       69 . The method according to  claim 65 , wherein M −  in the disalt is the conjugate base of a Bronsted acid selected from the group consisting of hydrochloric acid, nitric acid, sulfuric acid, hydrobromic acid, hydroiodic acid, perchloric acid, phosphoric acid, alkylsulfonic acids, arylsulfonic acids, halogenated alkylsulfonic acids, halogenated acetic acids, picric acid, oxalic acid, citric acid, formic acid, ascorbic acid and benzoic acid. 
   
   
       70 . The method of  claim 69 , wherein M −  is methanesulfonate, bromide, or chloride. 
   
   
       71 . The method according to  claim 66 , wherein M −  in the disalt is the conjugate base of a Bronsted acid selected from the group consisting of hydrochloric acid, nitric acid, sulfuric acid, hydrobromic acid, hydroiodic acid, perchloric acid, phosphoric acid, alkylsulfonic acids, arylsulfonic acids, halogenated alkylsulfonic acids, halogenated acetic acids, picric acid, oxalic acid, citric acid, formic acid, ascorbic acid and benzoic acid. 
   
   
       72 . The method of  claim 71 , wherein M −  is methanesulfonate, bromide, or chloride.